Novartis: EU approves biosimilar anti-inflammatory drug.
(CercleFinance.com) - Sandoz, Novartis' generic drugs unit, has received EU approval for a biosimilar version of Amgen's Enbrel to treat multiple inflammatory diseases.
The European Commission has approved Erelzi for use in Europe in all indications of its reference medicine.
It means Erelzi is approved for rheumatoid arthritis, axial spondyloarthritis, plaque psoriasis, and psoriatic arthritis, as well as juvenile idiopathic arthritis and pediatric plaque psoriasis.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The European Commission has approved Erelzi for use in Europe in all indications of its reference medicine.
It means Erelzi is approved for rheumatoid arthritis, axial spondyloarthritis, plaque psoriasis, and psoriatic arthritis, as well as juvenile idiopathic arthritis and pediatric plaque psoriasis.
Copyright (c) 2017 CercleFinance.com. All rights reserved.